TR200102239T2 - Beyaz kan hücreleri sayımını arttırmak için yöntem ve düzenlemeler. - Google Patents

Beyaz kan hücreleri sayımını arttırmak için yöntem ve düzenlemeler.

Info

Publication number
TR200102239T2
TR200102239T2 TR2001/02239T TR200102239T TR200102239T2 TR 200102239 T2 TR200102239 T2 TR 200102239T2 TR 2001/02239 T TR2001/02239 T TR 2001/02239T TR 200102239 T TR200102239 T TR 200102239T TR 200102239 T2 TR200102239 T2 TR 200102239T2
Authority
TR
Turkey
Prior art keywords
methods
blood cells
white blood
count
arrangements
Prior art date
Application number
TR2001/02239T
Other languages
English (en)
Turkish (tr)
Inventor
Trevor Macfarland Ronald
W. Miller Andrew
Original Assignee
Anormed Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc. filed Critical Anormed Inc.
Publication of TR200102239T2 publication Critical patent/TR200102239T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
TR2001/02239T 1999-02-02 2000-02-02 Beyaz kan hücreleri sayımını arttırmak için yöntem ve düzenlemeler. TR200102239T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11825599P 1999-02-02 1999-02-02

Publications (1)

Publication Number Publication Date
TR200102239T2 true TR200102239T2 (tr) 2002-01-21

Family

ID=22377471

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02239T TR200102239T2 (tr) 1999-02-02 2000-02-02 Beyaz kan hücreleri sayımını arttırmak için yöntem ve düzenlemeler.

Country Status (24)

Country Link
US (2) US6365583B1 (de)
EP (1) EP1148875B1 (de)
JP (2) JP4968868B2 (de)
KR (1) KR100643553B1 (de)
CN (1) CN1310642C (de)
AP (1) AP1497A (de)
AT (1) ATE268597T1 (de)
AU (2) AU772979B2 (de)
BR (1) BR0007924A (de)
CA (1) CA2361587C (de)
CZ (1) CZ20012698A3 (de)
DE (1) DE60011391T2 (de)
DK (1) DK1148875T3 (de)
ES (1) ES2222174T3 (de)
HK (1) HK1038319B (de)
HU (1) HUP0200100A3 (de)
IL (1) IL144400A (de)
MX (1) MXPA01007801A (de)
NO (1) NO20013770L (de)
NZ (1) NZ513602A (de)
PT (1) PT1148875E (de)
SI (1) SI1148875T1 (de)
TR (1) TR200102239T2 (de)
WO (1) WO2000045814A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
JP2003516984A (ja) * 1999-12-17 2003-05-20 アノーメッド・インコーポレイテッド ケモカインレセプターを結合する複素環式化合物
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
KR20030034184A (ko) * 2000-09-15 2003-05-01 아노르메드 인코포레이티드 케모킨 수용체 결합 헤테로사이클릭 화합물
KR20030029997A (ko) * 2000-09-15 2003-04-16 아노르메드 인코포레이티드 케모킨 수용체 결합 헤테로사이클릭 화합물
RU2311413C2 (ru) 2000-09-29 2007-11-27 Анормед, Инк. Циклические полиамины, содержащие в кольце n атомов азота, защищенных по принципу "все, кроме одного (n-1)", и способы их получения
MXPA04000982A (es) * 2001-07-31 2004-04-20 Anormed Inc Metodos para movilizar celulas progenitoras/madre.
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
WO2003022785A2 (en) * 2001-09-12 2003-03-20 Anormed Inc. Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
MXPA04006136A (es) * 2001-12-21 2004-11-01 Anormed Inc Compuestos heterociclicos que se unen a receptor de quimiocina con eficacia incrementada.
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
AU2003261723A1 (en) 2002-08-27 2004-03-19 Takeda Chemical Industries, Ltd. Cxcr4 antagonist and use thereof
CA2520259A1 (en) * 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
US7501518B2 (en) * 2003-04-22 2009-03-10 Genzyme Corporation Methods of making 2,6-diaryl piperidine derivatives
IN266744B (de) * 2003-04-22 2015-05-29 Genzyme Corp
CA2548393A1 (en) * 2003-12-11 2005-06-30 Anormed Inc. Chemokine receptor binding compounds
US7498346B2 (en) * 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
JP2008509928A (ja) * 2004-08-13 2008-04-03 アノーメド インコーポレイテッド 前駆／幹細胞を動員するためのケモカインの組み合わせ
EP1942890A4 (de) * 2005-06-15 2009-08-26 Genzyme Corp Chemokin-rezeptor-bindende verbindungen
US20070066624A1 (en) * 2005-08-16 2007-03-22 Anormed, Inc. Chemokine receptor binding compounds
MX2008010895A (es) * 2006-02-24 2008-09-03 Genzyme Corp Metodos para aumentar el flujo sanguineo y/o promover la regeneracion de tejidos.
RU2009107030A (ru) * 2006-08-02 2010-09-10 Джензим Корпорейшн (Us) Комбинированная терапия
MX2009001445A (es) * 2006-08-07 2009-02-18 Genzyme Corp Terapia de combinacion.
EP2094274A4 (de) 2006-12-21 2011-05-11 Biokine Therapeutics Ltd T-140 peptid-analoga mit cxcr4 superagonisten-aktivität für knochenmarkserholung
EP2396023A2 (de) 2009-02-11 2011-12-21 Yeda Research and Development Co. Ltd. Kurze peptide aus beta-defensin
CN102481332A (zh) 2009-06-14 2012-05-30 拜欧肯疗法有限公司 用于提高血小板水平的肽疗法
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP2014513727A (ja) * 2011-05-16 2014-06-05 ジェンザイム・コーポレーション Ｃｘｃｒ４拮抗薬の使用
EP2841084B1 (de) 2012-04-24 2018-05-30 Biokine Therapeutics Ltd. Cxcr4 antagonist peptid zur verwendung in der behandlung von lungenkrebs
WO2017009842A2 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
CN109069426B (zh) 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
DK3393468T3 (da) 2015-12-22 2022-12-19 X4 Pharmaceuticals Inc Fremgangsmåder til behandling af en immundefektsygdom
ES2830726T3 (es) 2016-02-23 2021-06-04 Biolinerx Ltd Método para seleccionar un régimen de tratamiento para la leucemia mieloide aguda (LMA)
JP2019510785A (ja) 2016-04-08 2019-04-18 エックス４ ファーマシューティカルズ， インコーポレイテッド 癌を処置する方法
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
US11332470B2 (en) 2016-06-21 2022-05-17 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
JP7084624B2 (ja) 2016-06-21 2022-06-15 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN109187337A (zh) * 2018-09-10 2019-01-11 南京工业职业技术学院 一种筛选强韧性FeAl晶界的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5021409A (en) * 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
US5612478A (en) 1995-03-30 1997-03-18 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en) 1995-05-02 1997-02-25 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
DE69929464T2 (de) * 1998-11-17 2006-09-07 Smithkline Beecham Corp. Zyklische polyamine zur behandlung der thrombozytopenie

Also Published As

Publication number Publication date
WO2000045814A1 (en) 2000-08-10
EP1148875B1 (de) 2004-06-09
AU2004203847A1 (en) 2004-09-09
IL144400A0 (en) 2002-05-23
HUP0200100A2 (hu) 2002-05-29
AU772979B2 (en) 2004-05-13
HUP0200100A3 (en) 2004-07-28
AP2001002221A0 (en) 2001-09-30
KR100643553B1 (ko) 2006-11-10
AU2527800A (en) 2000-08-25
HK1038319A1 (en) 2002-03-15
JP2002536329A (ja) 2002-10-29
JP4968868B2 (ja) 2012-07-04
AU2004203847B2 (en) 2007-03-22
CA2361587A1 (en) 2000-08-10
US6670354B2 (en) 2003-12-30
NO20013770L (no) 2001-09-27
ATE268597T1 (de) 2004-06-15
PT1148875E (pt) 2004-10-29
CN1310642C (zh) 2007-04-18
CA2361587C (en) 2010-04-20
US6365583B1 (en) 2002-04-02
ES2222174T3 (es) 2005-02-01
AP1497A (en) 2005-11-20
DK1148875T3 (da) 2004-10-18
NO20013770D0 (no) 2001-08-01
CN1338933A (zh) 2002-03-06
CZ20012698A3 (cs) 2002-03-13
HK1038319B (zh) 2005-03-18
KR20010101896A (ko) 2001-11-15
US20020058653A1 (en) 2002-05-16
MXPA01007801A (es) 2003-06-04
EP1148875A1 (de) 2001-10-31
DE60011391T2 (de) 2005-07-14
BR0007924A (pt) 2001-11-06
JP2011088937A (ja) 2011-05-06
DE60011391D1 (de) 2004-07-15
SI1148875T1 (en) 2004-12-31
NZ513602A (en) 2003-10-31
IL144400A (en) 2010-05-17

Similar Documents

Publication Publication Date Title
TR200102239T2 (tr) Beyaz kan hücreleri sayımını arttırmak için yöntem ve düzenlemeler.
TR200000482T2 (tr) N-Aroilfenilalanin türevleri.
TR199902552T2 (xx) Fungisidal triflorometilalkilamino-triazolopirimidinler.
TR200000481T2 (tr) N-Alkonoilfenilalenin türevleri.
EA200200619A1 (ru) Непептидильные ингибиторы vla-4-зависимого связывания клеток, применяемые при лечении воспалительных, аутоимунных и респираторных заболеваний
EA200100766A1 (ru) Хинолин-2-он замещенные гетероарильные производные, используемые в качестве противоопухолевых агентов
TR199700844T1 (xx) Pirazolil-Benzoil T�revleri.
HK1026691A1 (en) Substituted benzimidazoles and their use for treating retroviral infection
PA8504401A1 (es) Compuestos farmaceuticamente activos
ES2115163T3 (es) Procedimiento para inhibir la proliferacion de celulas de musculos lisos y la restinosis.
EA200100838A1 (ru) Конъюгаты гксф
TR199800436A2 (xx) Primidin t�revlerinin kanserin �nlenmesi i�in kullan�lmas�.
DK1485359T3 (da) Natriumkanalblokkere
AP9701039A0 (en) Derivatives of 2- (2-oxo-ethlidene)-imidazolidin-4-one.
TR200100672T2 (tr) Yeni izoksazolinon antibakteriyel ajanları
TR200100700T2 (tr) EtO2C--CH2-(R)Cgl-Aze-Pab-OH'nin kristalin formları
FR2382434A1 (fr) N'-(4-phenethyloxy substitue)phenyl) - n - methyl - n - methoxyurees et leur utilisation comme herbicides
TR200000635T2 (tr) Levosimendan'ın oral kompozisyonları.
TR200002237T2 (tr) Benzotiyadiazol ve türevleri
TR200001010T2 (tr) Ürokinaz önleyicileri olan izokinolinler.
TR200100636T2 (tr) Fosfoglikolipid ve bunun kullanım yöntemleri.
TR199700206A2 (xx) Floralkil- ve floralkoksi ikame edilmi� heterosiklik bradikinin-antagonistleri, bunlar�n imal edilmesine mahsus usul ve bunlar�n kullan�lmalar�.
SE8505887L (sv) Indoler
ES2117664T3 (es) Carboximetilmanoglucanos y derivados de los mismos.
KR930003908A (ko) 염증, 국소빈혈-유도된 세포의 손상 및 근디스트로피의 치료방법